東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Linked to FindBook

Google Book

Amazon

博客來

Nutritional and Metabolic Effects of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Nutritional and Metabolic Effects of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis./
Author:	Bailey, Julianna.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
Description:	70 p.
Notes:	Source: Dissertations Abstracts International, Volume: 83-07, Section: B.
Contained By:	Dissertations Abstracts International83-07B.
Subject:	Health education. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28862981
ISBN:	9798762198486

Nutritional and Metabolic Effects of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis.
Bailey, Julianna.

Nutritional and Metabolic Effects of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 70 p.

Source: Dissertations Abstracts International, Volume: 83-07, Section: B.

Thesis (Ph.D.)--The University of Alabama at Birmingham, 2021.

This item must not be sold to any third party vendors.

Background: Since malnutrition is a main clinical consequence of CF, a high-calorie, high-fat diet is recommended. Highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators promote improved growth and weight gain in subsets of the CF population. Recently Elexacaftor/Tezacaftor/Ivacaftor (ETI) was approved for use in up to 90% of people with CF. Our single center open-label observational cohort study aimed to explore changes in dietary and metabolic outcomes with use of ETI.Methods: Participants underwent baseline (V1) measurements prior to taking their first dose of ETI. Follow-up measurements were obtained at 28 days (V2) on ETI and > 6 months on drug (V3). Measurements at each time point included: weight, BMI, lung function, resting energy expenditure (REE%), hand grip strength (HGS), dietary intake, and enzyme dosage. Wilcoxon sign rank tests were used to compare changes in outcomes at each time point.Results: A total of 22 participants enrolled and completed baseline assessments. V2 was completed by 20 participants and 17 participants completed V3. Participants were 16-54 years of age (mean 26 years), and 50% were not previously taking CFTR modulators. Mean (± SD) BMI increased by 0.46 ± 0.93 kg/m² (p < 0.05) at V2 and 0.92 ± 0.88 kg/m² at V3 compared to V1 (p < 0.0001). REE% decreased by 6.6 ± 15.3 from V1 to V3 (p < 0.05). Total caloric intake increased by 297 ± 766 kcal/day (p < 0.05) and total fat intake increased by 19 ± 37 grams/day between V1 and V3 (p < 0.05).Conclusions: ETI increased BMI rapidly and this was sustained through at least 6 months. Decreased REE% combined with increased caloric intake are potential mechanisms of weight gain on ETI. Findings highlight the need for individualized nutritional counseling to improve diet quality and manage weight changes on ETI in the clinical setting.

ISBN: 9798762198486Subjects--Topical Terms:

559086
Health education.
Subjects--Index Terms:

BMI

Nutritional and Metabolic Effects of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis.
LDR:03085nmm a2200373 4500 001 2346526
005 20230315102235.5
006 m o d
007 cr#unu||||||||
008 241004s2021 ||||||||||||||||| ||eng d
020 $a 9798762198486
035 $a (MiAaPQ)AAI28862981
035 $a AAI28862981
040 $a MiAaPQ $c MiAaPQ
100 1 $a Bailey, Julianna. $3 3685637
245 1 0 $a Nutritional and Metabolic Effects of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 70 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-07, Section: B.
500 $a Advisor: Fontaine, Kevin.
502 $a Thesis (Ph.D.)--The University of Alabama at Birmingham, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Background: Since malnutrition is a main clinical consequence of CF, a high-calorie, high-fat diet is recommended. Highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators promote improved growth and weight gain in subsets of the CF population. Recently Elexacaftor/Tezacaftor/Ivacaftor (ETI) was approved for use in up to 90% of people with CF. Our single center open-label observational cohort study aimed to explore changes in dietary and metabolic outcomes with use of ETI.Methods: Participants underwent baseline (V1) measurements prior to taking their first dose of ETI. Follow-up measurements were obtained at 28 days (V2) on ETI and > 6 months on drug (V3). Measurements at each time point included: weight, BMI, lung function, resting energy expenditure (REE%), hand grip strength (HGS), dietary intake, and enzyme dosage. Wilcoxon sign rank tests were used to compare changes in outcomes at each time point.Results: A total of 22 participants enrolled and completed baseline assessments. V2 was completed by 20 participants and 17 participants completed V3. Participants were 16-54 years of age (mean 26 years), and 50% were not previously taking CFTR modulators. Mean (± SD) BMI increased by 0.46 ± 0.93 kg/m² (p < 0.05) at V2 and 0.92 ± 0.88 kg/m² at V3 compared to V1 (p < 0.0001). REE% decreased by 6.6 ± 15.3 from V1 to V3 (p < 0.05). Total caloric intake increased by 297 ± 766 kcal/day (p < 0.05) and total fat intake increased by 19 ± 37 grams/day between V1 and V3 (p < 0.05).Conclusions: ETI increased BMI rapidly and this was sustained through at least 6 months. Decreased REE% combined with increased caloric intake are potential mechanisms of weight gain on ETI. Findings highlight the need for individualized nutritional counseling to improve diet quality and manage weight changes on ETI in the clinical setting.
590 $a School code: 0005.
650 4 $a Health education. $3 559086
650 4 $a Nutrition. $3 517777
653 $a BMI
653 $a CFTR Modulation Therapy
653 $a Cystic Fibrosis
653 $a Nutrition
690 $a 0680
690 $a 0570
710 2 $a The University of Alabama at Birmingham. $b Health Education/Promotion (Public Health). $3 3177526
773 0 $t Dissertations Abstracts International $g 83-07B.
790 $a 0005
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28862981